IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

Texas Children's Hospital and Baylor College of Medicine are providing medication and other aid to fight sickle cell disease ...

Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...

WINSTON-SALEM, N.C. — Emory Moore, a 12-year-old treated at Brenner Children’s Hospital for sickle cell disease, received a special day with the Wake Forest basketball team. Despite her diagnosis, ...

Madhya Pradesh has achieved 100 per cent target by screening 90,98,902 persons for the sickle cell disease so far, a ...

Statistics from the district health department indicate that in 2023, suspected cases of sickle cells stood at 1,456 and in ...

A new study has found older-looking brains in adults with sickle cell disease, helping to explain the cognitive challenges experienced by such individuals. A brain image from a healthy individual ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

The Boring Company’s Hyperloop is set to revolutionize transportation in Texas! Promising ultra-fast travel and cutting-edge technology, this futuristic system is closer than ever to becoming a ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...